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Abstract
Background: Carbonic anhydrase 9 (CA9) is a marker for hypoxia and acidosis, which is linked
to a poor prognosis in human tumors. The purpose of this comparative analysis was to evaluate
whether CA9 and VEGF expression are associated with survival outcomes in patients with
metastatic colorectal cancer (mCRC) after treatment with bevacizumab as second or later line
treatment.
Methods:  Thirty-one mCRC patients who were treated with bevacizumab-containing
chemotherapy as second or later line treatment and who had analyzable tumor paraffin blocks were
selected for this study. The planned dose of bevacizumab was 5 mg/kg/2-week.
Immunohistochemical (IHC) staining of CA9 and VEGF was performed and their expression was
scored by the intensity multiplied by percentage of stained area.
Results: The overall response rate was 19.4% and the disease control rate (DCR) was 61.3% with
6 partial responses and 13 cases of stable disease. The DCR was significantly higher in patients with
a lower CA9 expression score compared to those with a higher score (80.0% vs. 27.3%,
respectively, P = 0.004). The patients with a low CA9 expression score also showed better
outcomes with regard to the median progression-free survival (P = 0.028) and overall survival (P =
0.026). However, VEGF expression was not associated with the DCR and survival.
Conclusion: Lower degree of CA9 expression was associated with better clinical outcomes in
patients with mCRC treated with lower dose bevacizumab-based chemotherapy. Prospective
studies are now needed to determine the correlation between CA9 expression and clinical
outcomes after bevacizumab treatment, at different doses and in varied settings.
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Background
For the patients with metastatic colorectal cancer
(mCRC), 5-fluorouracil (5-FU) based chemotherapy has
been the standard regimen [1,2]. Since the late 1990's,
combination chemotherapy with 5-FU/leucovorin (LV)
plus oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) has
been shown to improve the response rates and survival
when used as either first-line or second-line treatment [3-
5]. These combination regimens had been the treatment
of choice for patients with mCRC before the introduction
of bevacizumab.
Bevacizumab, a recombinant humanized monoclonal
antibody, targets vascular endothelial growth factor
(VEGF), and prevents its interaction with receptors on the
vascular endothelial cells that mediate angiogenesis; a
process critical for tumor progression [6,7]. Since the suc-
cessful results of a landmark study were published in 2004
[8], bevacizumab has been proven to be effective in sev-
eral clinical trials when combined with various cytotoxic
chemotherapeutic agents in patients with metastatic dis-
ease as first-line or neoadjuvant treatment before metasta-
sectomy [9-14]. Thus, bevacizumab plus 5-FU based
regimens are highly recommended in previously
untreated patients with mCRC. Bevacizumab-containing
combination chemotherapy also was proved to be effec-
tive as second-line treatment in a phase III trial, E3200
study; however, the approved dose for previously treated
patients based on the results from E3200 trial is twice as
high as that of first line treatment [15].
Tumor hypoxia is known to be associated with treatment
failure in several malignancies. Carbonic anhydrase 9
(CA9) is one of the representative markers for tumor
hypoxia; it is a transmembrane protein that plays a major
role in the adaptation and proliferation of cells, in
hypoxic and acidic conditions, by regulating the intracel-
lular and extracellular pH [16,17]. CA9 was initially iden-
tified in HeLa cells [18]; its expression has been found in
a variety of tumor types including colorectal cancer [19].
Hypoxia is one of driving forces of tumor angiogenesis;
therefore, expression of the hypoxia-inducible enzyme,
CA9, might be associated with the outcome of antiang-
iogenic treatment.
In this study, we aimed to investigate the efficacy of lower
dose bevacizumab (5 mg/kg/2-wk), a half of approved
dose for second-line setting, for pretreated patients. In
addition, clinicopathologic analysis was done to evaluate
the correlation between expression of CA9/VEGF and effi-
cacy of bevacizumab-containing regimen.
Methods
Patients and tissue samples
From July 2005 to October 2008, 50 patients with previ-
ously treated mCRC who received a lower dose of bevaci-
zumab were identified from a prospective medical
oncology patient database at the Center for Colorectal
Cancer, National Cancer Center, Korea. Among them,
study patients were selected according to the following
inclusion criteria: 1) patients that were exposed and
refractory to previous chemotherapy for metastatic disease
prior to treatment with bevacizumab; 2) one or more uni-
dimensionally measurable lesion(s) according to the
RECIST (Response Evaluation Criteria in Solid Tumors)
criteria [20] should be present; 3) planned dose of bevaci-
zumab should not be in excess of 5 mg/kg/2-wk; and 4)
adequate tumor paraffin blocks for immunohistochemi-
cal (IHC) staining should be available. Thirty one patients
were finally included in this study.
This study was conducted in accordance with the Helsinki
declaration and patients were provided with informed
consent prior to receiving the study treatment. Additional
informed consents for IHC staining were also obtained
where appropriate. The protocol was approved by the
Institutional Review Board of the National Cancer Center,
Korea (protocol number NCCNCS-08-120).
IHC staining for CA9 and VEGF expression was evaluated
by one pathologist (H. J. Chang) without knowledge of
the clinical findings. The comparative analysis of the clin-
ical results and CA9 and VEGF expression profiles was per-
formed by medical oncologists (Y.S. Hong and H.J. Cho).
Study treatment
Bevacizumab was administered at a dose of 5 mg/kg every
2 weeks or 7.5 mg/kg every 3 weeks on day 1, according to
the schedule of the concomitant chemotherapy regimen.
Concomitant cytotoxic chemotherapy regimens were cho-
sen by the attending physicians and included the follow-
ings: 2-week scheduled concomitant cytotoxic
chemotherapy with LV/5-FU (LV 200 mg/m2 d1, 5-FU 400
mg/m2 d1 and 5-FU 1200 mg/m2/day continuous infu-
sion d1–2), FOLFIRI (irinotecan 180 mg/m2 d1 and LV/5-
FU as above) and FOLFOX (oxaliplatin 85 mg/m2 d1 and
LV/5-FU as above), and a 3-week scheduled concomitant
regimen with oral fluoropyrimidines alone (capecitabine
2500 mg/m2/day or S-1 70 mg/m2/day d1–14). Dose
modifications of bevacizumab were not considered, but
delays of bevacizumab administration were permitted in
synchrony with the schedule of other cytotoxic chemo-
therapy. Dose modifications of combined cytotoxic drugs
were made for hematological or non-hematological toxic-
ity on the basis of the most severe grade of toxicity that
occurred during the previous cycle. Patients were treatedBMC Cancer 2009, 9:246 http://www.biomedcentral.com/1471-2407/9/246
Page 3 of 9
(page number not for citation purposes)
until disease progression, development of unacceptable
toxicity or patient refusal.
Assessments of efficacy and toxicity
Objective tumor responses were assessed every 6 weeks
using RECIST criteria; all responses required confirmation
at 4 weeks or later. Toxicities were graded according to the
National Cancer Institute Common Toxicity Criteria, ver-
sion 3.0 (NCI-CTC 3.0).
IHC stain for CA9 and VEGF
Immunostaining was performed using the labeled strepta-
vidin-biotin complex (LSAB) method, with primary anti-
bodies to CA9 (NB100-417, Novus Biologicals, CO, USA:
dilution 1:1000) and VEGF (G153-694, BD Pharmingen,
CA, USA: dilution 1:500). Formalin-fixed, paraffin-
embedded sections (4-μm thick) were dewaxed for 15
minutes in xylene and hydrated by passage through a
graded ethanol series to tap water. Antigen retrieval was
performed by incubation in a citrate buffer solution (Anti-
gen Unmasking Solution, Vector Laboratories, Burlin-
game, CA., USA) for 15 minutes in an 800-W microwave
oven. Reaction products were not detected when non-
immune serum or phosphate-buffered saline (PBS) was
used instead of the primary antibodies. Positive expres-
sion was classified as unequivocal brown staining of the
cell membranes (for CA9) or cytoplasm (for VEGF) of the
tumor cells (Figure 1). Immunohistochemical expression
was recorded as follows: 1) the intensity of the stain
defined as 0 for negative, 1+ for weak, 2+ for moderate,
and 3+ for strong (Figure 1); 2) the percent area was
defined as the percentage of stained tumor cells in the
entire tumor field; 3) the expression score was defined as
the intensity multiplied by the percent area positive for
tumor. A high CA9 and VEGF expression was defined by
an expression score ≥ 80.
Statistical analysis
All patients that showed adequate CA9 and VEGF IHC
results and received at least one course of bevacizumab
therapy were included in the survival analysis. Descriptive
statistics were reported as proportions and medians. The
chi-square test and the Fisher's exact test were used to
compare proportions. Usually a chi-square test was used,
but a Fisher's exact test was used if the expected value of
any of the cells of the contingency table was below 5. The
Wilcoxon rank-sum test was used to compare medians
between the patient groups. The overall survival (OS) and
the progression free survival (PFS) were assessed by the
Kaplan-Meier method and the 95% confidence interval
(95% CI) for the median time to an event was computed.
The log-rank test was used to compare survival outcomes
Immunohistochemical expression of CA9 (A to C) and VEGF (D to F) of strong (A and D), moderate (B and E), and weak (C  and F) intensities Figure 1
Immunohistochemical expression of CA9 (A to C) and VEGF (D to F) of strong (A and D), moderate (B and 
E), and weak (C and F) intensities.BMC Cancer 2009, 9:246 http://www.biomedcentral.com/1471-2407/9/246
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of the patient groups and the Cox proportional hazards
model was also used to examine the factors associated
with survival. The OS was measured from the start of bev-
acizumab therapy or from the date of first line chemother-
apy until death, censoring patients that had not died at the
date of the last follow up. The PFS was defined as the time
from the date of bevacizumab treatment to the date of dis-
ease progression or death by any cause, censoring patients
without progression at the date of the last disease assess-
ment. Analyses were performed using Stata version 10.0
(Stata Corp, College Station, Texas, USA).
Results
Patient characteristics
Between July 2005 and October 2008, 31 patients that
received bevacizumab as second or later line treatment,
and that had tumor paraffin blocks available for immu-
nostaining were selected for the study; the baseline patient
characteristics are described in Table 1. The median age
was 51.6 years (range: 31.8–67.8), 15 patients (48.4%)
were male and 19 patients (61.3%) had colon cancer as
their primary malignancy. Twenty-eight patients (90.3%)
had a good performance status (ECOG 0 or 1). The most
frequent site of metastasis was to the liver (17/31, 54.8%).
All 31 patients were exposed to three effective cytotoxic
drugs (fluoropyrimidines, irinotecan and oxaliplatin)
during their entire treatment period and 21 patients
(67.7%) were also exposed to cetuximab.
The CA9 expression was negative in 6 patients (19.4%),
weakly positive in 1 (3.2%), moderately positive in 11
(35.5%), and strongly positive in 13 patients (41.9%).
The mean value for the percent of stained area for the CA9
IHC was 30.1% (range, 0 – 95%) and the mean of expres-
sion score was 82.8 (range, 0 – 285). The patient charac-
teristics according to the CA9 expression are shown in
Table 1. There was no statistically significant differences in
patient characteristics between the groups according to
the CA9 expression scores, except for lymph node metas-
tases, which tended to be less frequent in patients with
higher CA9 expression (P = 0.081, by chi-square test). The
intensity of VEGF expression was negative in 7 (22.6%),
weakly positive in 9 (29.0%), moderately positive in 13
(41.9%), and strongly positive in 2 patients (6.5%). The
mean percent of stained area for VEGF was 44.5% (range,
0 – 90%) and the mean of expression score was 83.1
(range, 0 – 270). Patient characteristics were also evenly
distributed according to VEGF expression, except for more
frequent omental metastases in patients with lower VEGF
expression (data not shown).
Treatment delivery, toxicity and responses
In total, 200 cycles of lower dose bevacizumab were
administered with a median of 4.5 cycles per patient
(range 1 – 16 cycles). Fifteen patients (48.4%) received
FOLFOX as concomitant cytotoxic chemotherapy, 6
patients (19.3%) received FOLFIRI and 10 patients
(32.3%) received fluoropyrimidines alone (5-FU/LV in 7,
S-1 in 2 and capecitabine in 1 patient, respectively). These
study treatments were the second line treatment in 13
patients (41.9%) and third or later line treatment in 18
patients (58.1%). Combined chemotherapy and the line
of bevacizumab were balanced between groups with
higher and lower CA9 expression scores, without signifi-
cant differences. The median delivered dose intensity of
bevacizumab was 4.2 mg/kg/2-wk (84.0%). The grade 3
bevacizumab-related toxicities per patient included:
thromboembolism (1, 3.2%), bleeding (1, 3.2%) and
hypertension (1, 3.2%); grade 2 included proteinuria (5,
16.1%), bleeding (1, 3.2%) and hypertension (2, 6.4%).
The overall response rate was 19.4% (95% CI, 5.5 – 33.3)
and the disease control rate was 61.3% (95% CI, 44.2 –
78.4) with 0 complete response, 6 partial responses and
13 stable diseases (Table 1). There were statistically signif-
icant differences in the disease control rates; 80.0% (16/
20) in patients with a CA9 expression score < 80 and
27.3% (3/11) in those with a CA9 expression score ≥ 80
(P = 0.004). By contrast, the disease control rate was sim-
ilar in patients with lower VEGF expression compared to
those with higher VEGF expression (60.0% vs. 62.5%,
respectively. P = 0.919).
Survival
The survival outcomes are shown in Figures 2 and 3. The
median PFS was 3.9 months (95% CI, 1.7 – 6.1) and the
median OS with bevacizumab was 11.4 months (95% CI,
9.5 – 13.4), after the median 17.6 months of follow up
(range, 3.8 – 43.9). The median OS from initiation of
first-line treatment was 32.4 months (95% CI, 25.7 –
39.1). The PFS was better, with borderline significance, in
patients that received second line bevacizumab compared
to those that received third or later line bevacizumab (5.0
vs. 2.4 months, hazard ratio (HR) 0.49 [95% CI, 0.23–
1.05], P = 0.060); the OS was not statistically different
according to the line of bevacizumab treatment (16.4 vs.
11.2 months, HR 0.67 [95% CI, 0.24–1.83], P = 0.426).
In a comparative analysis based on the CA9 expression
scores, patients with a lower score (< 80) had improved
PFS with bevacizumab when compared to those with a
higher score (≥ 80) (4.7 months vs. 2.4 months, respec-
tively; HR 0.42 [95% CI, 0.18–0.94], P = 0.028). A lower
CA9 expression score was also associated with a better
overall survival compared to higher scores; 24.1 months
vs. 10.2 months, respectively (HR 0.35 [95% CI, 0.13–
0.92], P = 0.026). However, the PFS and the OS did not
differ between the subgroups based on higher or lower
VEGF expression scores: the median PFS of patients with
VEGF expression scores < 80 was 3.9 months, and thoseBMC Cancer 2009, 9:246 http://www.biomedcentral.com/1471-2407/9/246
Page 5 of 9
(page number not for citation purposes)
Table 1: Patient characteristics and treatment responses
Score of CA 9 expression
Patient characteristics (n = 31) <80 ≥ 80 P value
(n = 20) (n = 11)
Age, median
(range)
51.6
(31.8 – 67.8)
52.6
(33.3 – 66.7)
50.4
(31.8 – 67.8)
0.741*
Gender
Male 15 10 5 0.809†
Female 16 10 6
Performance status
03 2 1 1 . 0 0 0 ‡
12 5 1 6 9
23 2 1
Line of bevacizumab
2nd line 13 9 4 0.718‡
≥ 3rd line 18 11 7
Primary sites
Rectum 12 9 3 0.452‡
Colon 19 11 8
Site of distant metastasis
Liver 17 10 7 0.465†
Lymph node 15 12 3 0.081†
Lung 14 9 5 0.981†
Omentum 11 9 2 0.241‡
Bone 7 6 1 0.372‡
Sum of metastatic sites 4 3 1
< 3 20 13 7 1.000‡
≥ 31 1 7 4
Combined chemotherapy
FOLFOX 15 10 5 0.439‡
FOLFIRI 6 5 1
Fluoropyrimidines alone 10 5 5
Treatment responses
Complete response - - -
Partial response 6 (19.4%) 4 2
Stable disease 13 (41.9%) 12 1
Disease control rate§ 19 (61.3%) 16 (80.0%) 3 (27.3%) 0.004‡
Progressive disease 11 (35.5%) 3 8
Not evaluable 1 (3.2%) 1 0
*P value for age was calculated with the Wilcoxon rank-sum test.
†P values for gender, liver metastases, lymph node metastases, and lung metastases were calculated with use of the chi-square test.
‡P values for performance status, line of bevacizumab, omental metastases, bone metastases, sum of metastatic sites, combined chemotherapy, and 
disease control rate were calculated with the Fisher's exact test.
§Disease control rate = complete response + partial response + stable diseaseBMC Cancer 2009, 9:246 http://www.biomedcentral.com/1471-2407/9/246
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with higher VEGF expression scores had also 3.9 months
of PFS (HR 1.54 [95% CI, 0.72–3.30], P  = 0.25). The
median OS was 9.1 months for patients with VEGF expres-
sion scores < 80, whereas it was 11.5 months for those
with scores ≥ 80 (HR 1.66 [95% CI, 0.48–5.77], P = 0.68).
The median OS from initiation of first-line treatment
showed no statistically significant differences based on
the CA9 expression scores (P = 0.164) or VEGF expression
scores (P = 0.62).
The univariate analysis showed that there were five factors
associated with the PFS with a P value < 0.1: the CA9
expression score, gender, the line of treatment with beva-
cizumab, presence of bony metastases, and number of
metastatic sites. Multivariable analysis with the Cox
regression hazard model revealed that the CA9 expression
score and the number of metastatic sites were significantly
associated with the PFS: the risk of progression was signif-
icantly increased among patients with higher CA9 scores
compared to those with lower CA9 scores (HR = 3.50
[95% CI, 1.39–9.09]; P = 0.007) and for patients with 3 or
more metastatic sites compared to those with 1 or 2 met-
astatic sites (HR = 3.77 [95% CI, 1.27–11.40]; P = 0.016).
Discussion
In patients with mCRC, bevacizumab has become one of
highly recommended agents for first (5 mg/kg/2-wk) and
second line (10 mg/kg/2-wk) chemotherapy. There have
been many attempts to identify predictive biomarkers to
help select those patients that will benefit from targeted
agents, such as the association between the KRAS muta-
tion status and survival outcomes in patients with mCRC
treated with cetuximab [21]. As for bevacizumab, how-
ever, there are no predictive biomarkers identified to be
associated with either treatment response or survival in
patients with mCRC.
Both VEGF and CA9 are the products of hypoxia-induced
pathways. VEGF, a target of bevacizumab, is a critical com-
ponent of tumor angiogenesis. CA9, a transmembrane
protein, converts carbon dioxide to bicarbonate and
Survival outcomes according to the CA9 expression scores Figure 2
Survival outcomes according to the CA9 expression scores. The median PFS was 3.9 months and median OS with bev-
acizumab was 11.4 months; after the 17.6 months of median follow up of all 31 patients. There were statistically significant dif-
ferences between the 2 groups according to the score in terms of median PFS (4.7 mo vs. 2.4 mo, p = 0.028) and median OS 
(24.1 mo vs. 10.2 mo, p = 0.026).
The OS from initiation of first – line chemotherapy showed  no statistical difference based on CA9 expression scores Figure 3
The OS from initiation of first – line chemotherapy 
showed no statistical difference based on CA9 
expression scores.BMC Cancer 2009, 9:246 http://www.biomedcentral.com/1471-2407/9/246
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hydrogen, and thus regulates the microenvironment pH,
as well as influences other processes such as cell-cell adhe-
sion, proliferation, and invasion of tumor cells [22]. In
this study, we demonstrated that the degree of CA9
expression was associated with a survival benefit after
treatment with bevacizumab in previously treated
patients with mCRC; however, VEGF expression was not
related to the outcome of treatment in these patients. The
degree of CA9 expression was divided into high and low
using the expression score, which was defined as the
intensity multiplied by the percent of stained area; an
expression score ≥ 80 was considered to be high. The dis-
ease control rates were statistically higher, and the median
PFS and OS were statistically lengthened in patients with
low CA9 expression scores (< 80). Furthermore, CA9
expression remained significantly associated with the PFS
after adjustment for other risk factors in multivariable
analysis. The OS from initiation of first-line treatment,
however, was not statistically different based on the CA9
expression scores (Figure 3). Thus, CA9 expression could
be a predictive marker for a survival benefit, with bevaci-
zumab treatment, rather than a prognostic marker, in
patients with mCRC. The mechanism explaining the asso-
ciation of CA9 expression with bevacizumab resistance is
unclear. One possible explanation might be suggested by
the findings of Selvakumaran et al: where the antitumor
effects of bevacizumab were suggested to be dependent on
the susceptibility of tumors to hypoxia-induced apoptosis
[23]. CA9 accelerates CO2 removal from the intracellular
milieu as well as facilitates HCO3 
- recycling; thus, it serves
to protect the tumor cells from acidosis [24]. Therefore,
CA9 might play a role in the metabolic accommodation
during hypoxia and may induce resistance to hypoxia-
induced apoptosis by bevacizumab, although this
hypothesis requires confirmation.
However, in contrast to CA9, VEGF expression was not
associated with the clinical outcome of bevacizumab-
based therapy. VEGF is a target molecule of bevacizumab
and high levels of VEGF expression have been shown to be
associated with a poor prognosis in patients with colorec-
tal cancer [25]. In our study, however, there was no clini-
cal significance associated with VEGF expression after
bevacizumab treatment. In agreement with the results of
the current study, a prior study reported that tumor VEGF
expression was not a predictor of responsiveness to beva-
cizumab therapy [26].
The correlation between clinical outcomes and CA9
expression have been reported with several other malig-
nancies including cancer of the cervix [27], lung [28],
breast [29] and head and neck [30].
However, the most frequently reported studies associating
CA9 expression with tumor behavior have been in
patients with clear cell type renal cell carcinoma (RCC)
[31-33]. CA9 is strongly expressed by RCC and it is known
to be associated with clinical outcomes. Bui et al reported
low CA9 expression (defined as ≤ 85% of tumor cells) was
an independent predictor of poor prognosis after
nephrectomy [32] and Atkins et al reported CA9 expres-
sion was a predictor of responses to interleukin-2 therapy
[31]. Leibovich et al reported CA9 was not an independ-
ent predictor of clinical outcomes in patients with RCC
after adjusting for the nuclear grade and tumor necrosis
[34]; however, but it seemed to be true that CA9 expres-
sion was still one of the factors associated with RCC prog-
nosis. In patients with RCC, a higher expression of CA9
was associated with better survival outcomes.
In terms of prediction of a survival benefit from bevacizu-
mab, it has been reported that low CA9 expression was
associated with better survival outcomes in patients with
malignant astrocytoma treated with bevacizumab plus iri-
notecan [35]. From a phase II trial of bevacizumab plus
irinotecan in patients with malignant astrocytoma, a com-
parative analysis was performed with several angiogenic
factors including CA9 from tumor specimens by Sathorn-
sumette et al. This phase II trial adopted a high dose regi-
men of bevacizumab, 10 mg/kg/2-wk [36]. They reported
that a higher VEGF expression was associated with radio-
logical responses to bevacizumab, but not with overall
survival, and that the CA9 expression was associated with
overall survival but not with radiological responses to
bevacizumab. To the best of our knowledge, current study
firstly suggested the predictive role of CA9 for DCR and
PFS in bevacizumab-treated patients.
This study has another advantage showing that lower dose
of bevacizumab at 5 mg/kg/2-wk could also result in clin-
ical responses in the second line setting and even in the
third or later line. Angiogenesis with VEGF is essential
during the early stages of tumor progression; VEGF is
expressed throughout the entire tumor life cycle. How-
ever, as more time elapses other factors in addition to
VEGF itself become important at later stages of progres-
sion [37]. Therefore, it can be inferred that bevacizumab
is more likely to be effective during the earlier stages of
cancer, and that higher doses of bevacizumab may be
needed to suppress the already activated VEGF pathways
during later stages. Thus, the dose for phase III clinical tri-
als using second-line treatment has been determined to be
10 mg/kg/2-wk, based on several preclinical and clinical
studies that showed a dose-dependent effect of bevacizu-
mab [15,38,39]. From a phase III trial comparing FOL-
FOX plus bevacizumab with FOLFOX plus placebo,
second-line treatment with bevacizumab was demon-
strated to be effective: the median PFS and OS were 7.3
months and 12.9 months with a 22.7% response rate
[15]. However, recent clinical data on bevacizumab as firstBMC Cancer 2009, 9:246 http://www.biomedcentral.com/1471-2407/9/246
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line treatment for non-small cell lung cancer and colorec-
tal cancer demonstrated that there was no significant dif-
ference in the response rate and survival between lower
dose and higher dose treatment groups[40,41] Although a
phase II trial of lower dose of bevacizumab (5 mg/kg/2-
wk) plus 5-FU/LV as a 3rd-line treatment failed to show
clinical benefits [42], the lower dose still remained to be
explored in second-line setting. In this study, 13 patients
were treated with second line bevacizumab at 5 mg/kg/2-
wk; 4 patients (30.8%) had confirmed partial responses
and the median PFS was 5.0 months, which was not infe-
rior to previous study. Furthermore, among 18 patients
treated with third line or later bevacizumab, at 5 mg/kg/2-
wk, 2 confirmed responses were observed (2/18, 11.1%)
and the median PFS was lengthened to 4.5 months (95%
CI, 1.0 – 8.3) for 11 patients that had a low CA9 expres-
sion score.
This study includes several limitations as follow: 1) the
line of treatment with bevacizumab and concomitant
chemotherapy were not constant, 2) this was a retrospec-
tive study with a small sample size, and the analysis had
low statistical power, 3) patients without analyzable par-
affin blocks were excluded, eliminating some of the
patients treated with bevacizumab as second or later line
therapy. Further evaluation of CA9 in patients enrolled in
randomized prospective trials may confirm the use of CA9
as a marker in patients receiving bevacizumab therapy.
Conclusion
In conclusion, CA9 IHC stain can be easily performed in
clinical practice and it can be used to predict survival ben-
efit in patients with previously treated mCRC who are
considered to be treated with lower dose of bevacizumab
as second or later lines. Further prospective, comparative
analysis between the degree of CA9 expression and clini-
cal outcomes in mCRC patients with 1st line or higher
dose of bevacizumab will be warranted.
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